Nektar planning Phase III testing of immuno-oncology combo based on Phase I/II response rates

Nektar Therapeutics (NASDAQ:NKTR) said it will start Phase III testing of its NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab based on lower-than-expected Phase I/II response rates reported at the American Society of Clinical Oncology meeting in Chicago. The market's response implied skepticism that substantially lower response rates among patients

Read the full 488 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE